New treatment for acute myelogenous leukemia

Courtney D. DiNardo, Jorge E. Cortes

Research output: Contribution to journalReview article

Abstract

Introduction: Acute myelogenous leukemia (AML) is a genetically heterogeneous disease. Yet current therapy has changed little over the decades and includes the nucleoside analog cytarabine in combination with an anthracycline as primary therapy. With this approach, durable cures occur in the minority of patients. With the recent improved scientific understanding of the underlying genetic and epigenetic aberrations in AML, there is now the potential of individualized and targeted therapeutic approaches for the curative treatment of AML.

Areas covered: The focus of this article is to review the therapeutic potential of many of the novel agents currently under investigation in the treatment of acute myeloid leukemia. The results of pivotal Phase III studies, as well as ongoing Phase II and III studies and selected Phase I studies with impact on the field of AML therapy will be discussed.

Expert opinion: Advances in the scientific knowledge of the various genetic and epigenetic alterations in AML, in conjunction with more effective, rationally designed and/or novel targeted therapeutics, offers a real hope and expectation of improved AML outcomes in the future.

Original languageEnglish (US)
Pages (from-to)95-106
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Therapeutics
Epigenomics
Anthracyclines
Cytarabine
Expert Testimony
Nucleosides

Keywords

  • Acute myelogenous leukemia
  • Future directions
  • Targeted therapy
  • Treatment review

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

New treatment for acute myelogenous leukemia. / DiNardo, Courtney D.; Cortes, Jorge E.

In: Expert Opinion on Pharmacotherapy, Vol. 16, No. 1, 01.01.2015, p. 95-106.

Research output: Contribution to journalReview article

DiNardo, Courtney D. ; Cortes, Jorge E. / New treatment for acute myelogenous leukemia. In: Expert Opinion on Pharmacotherapy. 2015 ; Vol. 16, No. 1. pp. 95-106.
@article{11b4d81be5a348e78a1ecbd17d14ede7,
title = "New treatment for acute myelogenous leukemia",
abstract = "Introduction: Acute myelogenous leukemia (AML) is a genetically heterogeneous disease. Yet current therapy has changed little over the decades and includes the nucleoside analog cytarabine in combination with an anthracycline as primary therapy. With this approach, durable cures occur in the minority of patients. With the recent improved scientific understanding of the underlying genetic and epigenetic aberrations in AML, there is now the potential of individualized and targeted therapeutic approaches for the curative treatment of AML.Areas covered: The focus of this article is to review the therapeutic potential of many of the novel agents currently under investigation in the treatment of acute myeloid leukemia. The results of pivotal Phase III studies, as well as ongoing Phase II and III studies and selected Phase I studies with impact on the field of AML therapy will be discussed.Expert opinion: Advances in the scientific knowledge of the various genetic and epigenetic alterations in AML, in conjunction with more effective, rationally designed and/or novel targeted therapeutics, offers a real hope and expectation of improved AML outcomes in the future.",
keywords = "Acute myelogenous leukemia, Future directions, Targeted therapy, Treatment review",
author = "DiNardo, {Courtney D.} and Cortes, {Jorge E.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1517/14656566.2015.981527",
language = "English (US)",
volume = "16",
pages = "95--106",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - New treatment for acute myelogenous leukemia

AU - DiNardo, Courtney D.

AU - Cortes, Jorge E.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Introduction: Acute myelogenous leukemia (AML) is a genetically heterogeneous disease. Yet current therapy has changed little over the decades and includes the nucleoside analog cytarabine in combination with an anthracycline as primary therapy. With this approach, durable cures occur in the minority of patients. With the recent improved scientific understanding of the underlying genetic and epigenetic aberrations in AML, there is now the potential of individualized and targeted therapeutic approaches for the curative treatment of AML.Areas covered: The focus of this article is to review the therapeutic potential of many of the novel agents currently under investigation in the treatment of acute myeloid leukemia. The results of pivotal Phase III studies, as well as ongoing Phase II and III studies and selected Phase I studies with impact on the field of AML therapy will be discussed.Expert opinion: Advances in the scientific knowledge of the various genetic and epigenetic alterations in AML, in conjunction with more effective, rationally designed and/or novel targeted therapeutics, offers a real hope and expectation of improved AML outcomes in the future.

AB - Introduction: Acute myelogenous leukemia (AML) is a genetically heterogeneous disease. Yet current therapy has changed little over the decades and includes the nucleoside analog cytarabine in combination with an anthracycline as primary therapy. With this approach, durable cures occur in the minority of patients. With the recent improved scientific understanding of the underlying genetic and epigenetic aberrations in AML, there is now the potential of individualized and targeted therapeutic approaches for the curative treatment of AML.Areas covered: The focus of this article is to review the therapeutic potential of many of the novel agents currently under investigation in the treatment of acute myeloid leukemia. The results of pivotal Phase III studies, as well as ongoing Phase II and III studies and selected Phase I studies with impact on the field of AML therapy will be discussed.Expert opinion: Advances in the scientific knowledge of the various genetic and epigenetic alterations in AML, in conjunction with more effective, rationally designed and/or novel targeted therapeutics, offers a real hope and expectation of improved AML outcomes in the future.

KW - Acute myelogenous leukemia

KW - Future directions

KW - Targeted therapy

KW - Treatment review

UR - http://www.scopus.com/inward/record.url?scp=84917708460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84917708460&partnerID=8YFLogxK

U2 - 10.1517/14656566.2015.981527

DO - 10.1517/14656566.2015.981527

M3 - Review article

C2 - 25480777

AN - SCOPUS:84917708460

VL - 16

SP - 95

EP - 106

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 1

ER -